Verona Pharma plc (VRNA) Comparison with companies in other sectors?

Verona Pharma plc has a share price of 84.98M. You can analyze Verona Pharma plc (VRNA) competitors across different market sectors through stock heatmaps.

What are VRNA's NET and operating margins?

Verona Pharma plc (VRNA) operating margin is around -1.16, and net profit margin is approximately -1.38 as of the latest reports.

In what way does VRNA's earnings per share (EPS) trend reflect its financial momentum?

Verona Pharma plc (VRNA) EPS is -2.00 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Verona Pharma plc is -52.42, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Verona Pharma plc?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Verona Pharma plc like P/E which is -54.30, P/B which is 39.31, and PEG which is -7.33. Compare them with sector averages to evaluate if the stock is priced fairly.

Verona Pharma plc

VRNA•NASDAQ

Healthcare

Biotechnology

$104.84

$0.07(0.07%)

Fundamental Analysis of Verona Pharma plc (VRNA)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-2.00

P/E Ratio

-52.42

ROE

-0.90%

Net Margin

-1.38%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$8.91B

Shares OutstandingTotal number of shares issued

$84.98M

Book Value/ShareNet worth per share

$0.33

Revenue/ShareAnnual revenue per share

$0.17

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-2

Net MarginNet income as percentage of revenue

-138.37%

Operating MarginOperating income as percentage of revenue

-116.27%

ROEReturn on shareholders' equity

-89.89%

ROAReturn on total assets

-31.19%

ROCEReturn on capital employed

-29.36%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.18

Cash/ShareCash and equivalents per share

$0.59

FCF YieldFree cash flow as percentage of market cap

-1.35%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for VRNAFinancial Ratios Analysis details for VRNA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for VRNASector Benchmarking details for VRNA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Verona Pharma plc Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Verona Pharma plc. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Verona Pharma plc's unique business strengths and challenges.

Key Financial Metrics for Verona Pharma plc

For Verona Pharma plc, essential financial indicators include EPS -2.00, PE -52.42, and ROE -0.90. These key ratios reveal insights into Verona Pharma plc's profitability, valuation, and operational health. Understanding these metrics enables you to compare Verona Pharma plc with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Verona Pharma plc

Metrics like Net Margin -138.37% and ROA -31.19% shed light on how well Verona Pharma plc is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Verona Pharma plc can sustain its operations and continue growing in the future.

Valuation and Market Position of Verona Pharma plc

Using ratios such as P/B Ratio 39.31 and PEG Ratio -7.33, investors can assess whether Verona Pharma plc is appropriately valued based on its financials and growth potential. These figures, combined with Verona Pharma plc's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Verona Pharma plc

Financial health indicators, such as Debt/Equity Ratio 0.009 and Cash Flow $-0.18, provide a snapshot of Verona Pharma plc's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Verona Pharma plc, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Verona Pharma plc

Investing in Verona Pharma plc based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Verona Pharma plc focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;